How the gut bacterium Akkermansia binds to and uses intestinal mucus
Mechanisms of mucin binding and acquisition by Akkermansia
Researchers are learning how the gut microbe Akkermansia grabs and eats the mucus lining in the intestine, which could help people with obesity and other metabolic conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11306444 on NIH RePORTER |
What this research studies
From your point of view, this work looks at the tiny machinery Akkermansia uses to stick to and break down the mucus that lines the gut. Scientists will use genetic changes, protein analysis, and cell biology experiments in the lab to define a newly discovered mucin transporter and related surface proteins. They will also track how these systems work with mucin-degrading enzymes and how mucin metabolism helps Akkermansia compete with other microbes and affect host sterol biology. The goal is to produce knowledge that could someday inform probiotic or microbiome-based treatments for metabolic health.
Who could benefit from this research
Good fit: People with obesity, metabolic syndrome, or interest in microbiome-based approaches would be the most likely future candidates to benefit from therapies informed by this research.
Not a fit: Patients needing immediate clinical interventions or those whose conditions are unrelated to gut microbiota are unlikely to see direct benefit from this basic laboratory research in the short term.
Why it matters
Potential benefit: If successful, this work could guide development of new probiotic or microbiome therapies to improve metabolic health such as obesity and related conditions.
How similar studies have performed: Animal studies and early human work suggest Akkermansia relates to better metabolism and is being explored as a probiotic, but the detailed molecular mechanisms targeted here remain novel.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Valdivia, Raphael H — Duke University
- Study coordinator: Valdivia, Raphael H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.